CA2612751A1 - Vegf-containing transport media composition for storing cells engrafted in a biocompatible matrix - Google Patents
Vegf-containing transport media composition for storing cells engrafted in a biocompatible matrix Download PDFInfo
- Publication number
- CA2612751A1 CA2612751A1 CA 2612751 CA2612751A CA2612751A1 CA 2612751 A1 CA2612751 A1 CA 2612751A1 CA 2612751 CA2612751 CA 2612751 CA 2612751 A CA2612751 A CA 2612751A CA 2612751 A1 CA2612751 A1 CA 2612751A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- implantable material
- media composition
- graft
- cryopreservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 177
- 239000000203 mixture Substances 0.000 title claims abstract description 156
- 239000006163 transport media Substances 0.000 title claims description 55
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 239000000463 material Substances 0.000 claims abstract description 434
- 210000004027 cell Anatomy 0.000 claims abstract description 400
- 238000000034 method Methods 0.000 claims abstract description 219
- 206010016717 Fistula Diseases 0.000 claims abstract description 135
- 230000003890 fistula Effects 0.000 claims abstract description 135
- 230000002792 vascular Effects 0.000 claims abstract description 125
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 78
- 230000003872 anastomosis Effects 0.000 claims abstract description 75
- 238000000502 dialysis Methods 0.000 claims abstract description 72
- 230000035800 maturation Effects 0.000 claims abstract description 54
- 230000002093 peripheral effect Effects 0.000 claims abstract description 53
- 230000009969 flowable effect Effects 0.000 claims abstract description 44
- 238000002513 implantation Methods 0.000 claims abstract description 30
- 230000017531 blood circulation Effects 0.000 claims description 106
- 239000012595 freezing medium Substances 0.000 claims description 53
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 42
- 210000001519 tissue Anatomy 0.000 claims description 42
- 238000003860 storage Methods 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 34
- 239000012091 fetal bovine serum Substances 0.000 claims description 31
- 206010003226 Arteriovenous fistula Diseases 0.000 claims description 30
- 230000010354 integration Effects 0.000 claims description 30
- 238000005138 cryopreservation Methods 0.000 claims description 29
- 230000003833 cell viability Effects 0.000 claims description 27
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 27
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 27
- 238000007710 freezing Methods 0.000 claims description 25
- 230000008014 freezing Effects 0.000 claims description 25
- 238000004113 cell culture Methods 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 24
- 150000004676 glycans Chemical class 0.000 claims description 23
- 229920001282 polysaccharide Polymers 0.000 claims description 23
- 239000005017 polysaccharide Substances 0.000 claims description 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 22
- 238000001631 haemodialysis Methods 0.000 claims description 22
- 230000000322 hemodialysis Effects 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 238000010899 nucleation Methods 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- 230000004663 cell proliferation Effects 0.000 claims description 14
- 230000023753 dehiscence Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 12
- 230000036772 blood pressure Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000013508 migration Methods 0.000 claims description 11
- 230000003836 peripheral circulation Effects 0.000 claims description 11
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 10
- 229920002307 Dextran Polymers 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 230000002338 cryopreservative effect Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 7
- 239000000560 biocompatible material Substances 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 210000003752 saphenous vein Anatomy 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 230000009977 dual effect Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 210000003191 femoral vein Anatomy 0.000 claims description 5
- 230000003252 repetitive effect Effects 0.000 claims description 5
- 230000012292 cell migration Effects 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 229920004934 Dacron® Polymers 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 210000001758 mesenteric vein Anatomy 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 210000003606 umbilical vein Anatomy 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 239000013028 medium composition Substances 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 abstract description 29
- 230000015572 biosynthetic process Effects 0.000 abstract description 25
- 210000003462 vein Anatomy 0.000 description 67
- 238000001356 surgical procedure Methods 0.000 description 60
- 239000007943 implant Substances 0.000 description 51
- 208000031481 Pathologic Constriction Diseases 0.000 description 42
- 230000036262 stenosis Effects 0.000 description 40
- 208000037804 stenosis Diseases 0.000 description 40
- 238000012360 testing method Methods 0.000 description 39
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 28
- 239000003636 conditioned culture medium Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 229920002971 Heparan sulfate Polymers 0.000 description 23
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 22
- 208000007536 Thrombosis Diseases 0.000 description 21
- 238000002604 ultrasonography Methods 0.000 description 20
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 18
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 238000002583 angiography Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 210000001367 artery Anatomy 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 108010010803 Gelatin Proteins 0.000 description 13
- 210000002403 aortic endothelial cell Anatomy 0.000 description 13
- 230000010261 cell growth Effects 0.000 description 13
- 230000003511 endothelial effect Effects 0.000 description 13
- 239000008273 gelatin Substances 0.000 description 13
- 229920000159 gelatin Polymers 0.000 description 13
- 235000019322 gelatine Nutrition 0.000 description 13
- 235000011852 gelatine desserts Nutrition 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 238000002399 angioplasty Methods 0.000 description 12
- 235000011089 carbon dioxide Nutrition 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 238000012423 maintenance Methods 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 10
- 230000035899 viability Effects 0.000 description 10
- 208000034906 Medical device complication Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000003484 anatomy Anatomy 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 206010020718 hyperplasia Diseases 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 239000000565 sealant Substances 0.000 description 9
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000003878 venous anastomosis Effects 0.000 description 8
- 229930182566 Gentamicin Natural products 0.000 description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 7
- 230000021164 cell adhesion Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229960002518 gentamicin Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 210000004731 jugular vein Anatomy 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000000750 progressive effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000000149 penetrating effect Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 230000000246 remedial effect Effects 0.000 description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000002785 anti-thrombosis Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000002302 brachial artery Anatomy 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 201000000523 end stage renal failure Diseases 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000003284 homeostatic effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000008719 thickening Effects 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 206010048671 Venous stenosis Diseases 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940059329 chondroitin sulfate Drugs 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000002594 fluoroscopy Methods 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002608 intravascular ultrasound Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 230000002966 stenotic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 229920002274 Nalgene Polymers 0.000 description 3
- 206010050902 Postoperative thrombosis Diseases 0.000 description 3
- 239000004792 Prolene Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000004191 axillary artery Anatomy 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000010595 endothelial cell migration Effects 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 244000052637 human pathogen Species 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011236 particulate material Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 210000002321 radial artery Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000015590 smooth muscle cell migration Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 231100000164 trypan blue assay Toxicity 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- YAYLYOCENKWKIB-JYJNAYRXSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(2s)-2-amino-3-(4-methoxyphenyl)propanoyl]amino]-4-oxobutanoic acid Chemical compound COC1=CC=C(C[C@H](N)C(=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N)C=C1 YAYLYOCENKWKIB-JYJNAYRXSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 2
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- 108010056764 Eptifibatide Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 238000006595 Griess deamination reaction Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010060872 Transplant failure Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 108010037725 arginine-glycine-aspartate-O-methyltyrosine amide Proteins 0.000 description 2
- 230000003881 arterial anastomosis Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 210000002048 axillary vein Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000003090 iliac artery Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010051268 Anastomotic stenosis Diseases 0.000 description 1
- 241001522301 Apogonichthyoides nigripinnis Species 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 208000009087 False Aneurysm Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010051269 Graft thrombosis Diseases 0.000 description 1
- 101000869693 Homo sapiens Protein S100-A9 Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108010081391 Ristocetin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010048975 Vascular pseudoaneurysm Diseases 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229940000279 aggrastat Drugs 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- VZUGBLTVBZJZOE-KRWDZBQOSA-N n-[3-[(4s)-2-amino-1,4-dimethyl-6-oxo-5h-pyrimidin-4-yl]phenyl]-5-chloropyrimidine-2-carboxamide Chemical compound N1=C(N)N(C)C(=O)C[C@@]1(C)C1=CC=CC(NC(=O)C=2N=CC(Cl)=CN=2)=C1 VZUGBLTVBZJZOE-KRWDZBQOSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950004257 ristocetin Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002559 ulnar artery Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3808—Endothelial cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2818182 CA2818182C (en) | 2005-06-21 | 2006-06-05 | Methods and compositions for enhancing vascular access |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69270805P | 2005-06-21 | 2005-06-21 | |
| US60/692,708 | 2005-06-21 | ||
| USPCT/US2005/043967 | 2005-12-06 | ||
| PCT/US2005/043967 WO2006062909A2 (en) | 2004-12-08 | 2005-12-06 | Methods and compositions for enhancing vascular access |
| PCT/US2006/021755 WO2007001744A2 (en) | 2005-06-21 | 2006-06-05 | Methods and compositions for enhancing vascular access |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2818182 Division CA2818182C (en) | 2005-06-21 | 2006-06-05 | Methods and compositions for enhancing vascular access |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2612751A1 true CA2612751A1 (en) | 2007-01-04 |
Family
ID=39892157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2612751 Abandoned CA2612751A1 (en) | 2005-06-21 | 2006-06-05 | Vegf-containing transport media composition for storing cells engrafted in a biocompatible matrix |
| CA 2818182 Expired - Fee Related CA2818182C (en) | 2005-06-21 | 2006-06-05 | Methods and compositions for enhancing vascular access |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2818182 Expired - Fee Related CA2818182C (en) | 2005-06-21 | 2006-06-05 | Methods and compositions for enhancing vascular access |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20090035346A1 (enExample) |
| EP (2) | EP2361591A3 (enExample) |
| JP (2) | JP5632580B2 (enExample) |
| CN (3) | CN101257861B (enExample) |
| AU (1) | AU2006262682B2 (enExample) |
| CA (2) | CA2612751A1 (enExample) |
| ES (1) | ES2541684T3 (enExample) |
| IL (2) | IL188263A (enExample) |
| SG (2) | SG161258A1 (enExample) |
| WO (1) | WO2007001744A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2926510B2 (ja) | 1990-08-09 | 1999-07-28 | 京都電子工業株式会社 | アンモニア濃度測定装置 |
| AU2006238892B2 (en) | 2005-04-21 | 2011-01-27 | Massachusetts Institute Of Technology | Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs |
| US20090035346A1 (en) | 2005-06-21 | 2009-02-05 | Pervasis Therpeutics, Inc. | Methods and Compositions for Enhancing Vascular Access |
| WO2008057590A2 (en) * | 2006-11-07 | 2008-05-15 | Pervasis Therapeutics, Inc. | Methods and compositions for modulating tissue modeling |
| US20100092532A1 (en) * | 2006-11-07 | 2010-04-15 | Helen Marie Nugent | Materials and Methods for Treating and Managing Angiogenesis-Mediated Diseases |
| JP5806466B2 (ja) * | 2008-01-28 | 2015-11-10 | バイオメット・３アイ・エルエルシー | 親水性を向上させたインプラント表面 |
| WO2012149451A1 (en) * | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| CN102763642B (zh) * | 2012-08-14 | 2014-04-02 | 郑州赛英科干细胞技术有限公司 | 一种冷冻保护液以及冷冻保存人胎盘羊膜和绒毛膜的方法 |
| CN107670109A (zh) * | 2014-05-27 | 2018-02-09 | 诺瓦赫普有限公司 | 经生物工程改造的同种异体瓣膜 |
| AU2016228986B2 (en) * | 2015-03-10 | 2021-02-04 | Stent Tek Limited | Surgical system, device and methods of use thereof for the percutaneous creation of an arteriovenous fistula (AVF) |
| US12017032B1 (en) | 2017-11-13 | 2024-06-25 | Sbr Innovations, Llc | Arteriovenous graft and method of using thereof |
| US11389622B1 (en) * | 2017-11-13 | 2022-07-19 | Simon B. Rayhanabad | Patch for providing dialysis |
| US11918223B2 (en) | 2018-02-02 | 2024-03-05 | University Of Louisville Research Foundation, Inc. | Sutureless graft anastomotic quick connect system |
| IL311092B2 (en) * | 2018-08-31 | 2025-05-01 | Wisconsin Alumni Res Found | Fabrication of vascular grafts seeded with arterial endothelial cells |
| US12310836B2 (en) | 2020-03-03 | 2025-05-27 | Akeo Hagiwara | Vein cover |
| CN115376392B (zh) * | 2022-08-18 | 2024-04-26 | 昆明理工大学 | 主动脉老化对血管生物力学影响的模拟装置及方法 |
| EP4439070B1 (de) * | 2023-03-27 | 2025-12-03 | Siemens Healthcare Diagnostics Products GmbH | Automatisches analysesystem |
| CN120227529B (zh) * | 2025-05-29 | 2025-08-12 | 鼎科医疗技术（苏州）有限公司 | 一种血管外支架 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418691A (en) * | 1981-10-26 | 1983-12-06 | Massachusetts Institute Of Technology | Method of promoting the regeneration of tissue at a wound |
| US4787900A (en) * | 1982-04-19 | 1988-11-29 | Massachusetts Institute Of Technology | Process for forming multilayer bioreplaceable blood vessel prosthesis |
| US4820626A (en) * | 1985-06-06 | 1989-04-11 | Thomas Jefferson University | Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself |
| IL78950A (en) | 1985-06-06 | 1991-12-15 | Univ Jefferson | Coating for prosthetic devices |
| US4732155A (en) * | 1985-08-27 | 1988-03-22 | The Children's Medical Center Corporation | Implantable chemoattractant system |
| US5863531A (en) * | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
| US6309635B1 (en) * | 1986-11-20 | 2001-10-30 | Children's Medical Center Corp. | Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo |
| CA1340581C (en) * | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5567612A (en) * | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
| US5804178A (en) * | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| US5736372A (en) * | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
| US5145769A (en) * | 1987-08-21 | 1992-09-08 | Cryolife Inc. | Method for cryopreserving blood vessels |
| US5202120A (en) * | 1987-09-11 | 1993-04-13 | Case Western Reserve University | Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
| US4945086A (en) | 1988-05-03 | 1990-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Smooth muscle cell growth inhibitor |
| US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
| US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| CH676195A5 (enExample) * | 1988-10-07 | 1990-12-28 | Sulzer Ag | |
| JPH03133901A (ja) * | 1989-10-19 | 1991-06-07 | Osaka Gas Co Ltd | 生体細胞の凍結保存方法 |
| US5527532A (en) * | 1989-11-13 | 1996-06-18 | President And Fellows Of Harvard College | Extraluminal regulation of the growth and repair of tubular structures in vivo |
| WO1991007154A1 (en) * | 1989-11-13 | 1991-05-30 | President And Fellows Of Harvard College | EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO |
| US5540928A (en) * | 1991-02-27 | 1996-07-30 | President And Fellows Of Harvard College | Extraluminal regulation of the growth and repair of tubular structures in vivo |
| CA2071137A1 (en) * | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
| CA2113089C (en) | 1991-07-15 | 2007-11-06 | Peter J. Sims | Universal donor cells |
| US5336615A (en) | 1992-01-06 | 1994-08-09 | Yale University | Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity |
| JPH0646840A (ja) * | 1992-08-04 | 1994-02-22 | Nippon Zenyaku Kogyo Kk | 細胞凍結保存液 |
| US5399665A (en) * | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5981568A (en) * | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) * | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| GB9306449D0 (en) * | 1993-03-29 | 1993-05-19 | Nat Heart Research Fund | Tissue equivalents |
| US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| US5645829A (en) * | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US6176874B1 (en) * | 1993-10-18 | 2001-01-23 | Masschusetts Institute Of Technology | Vascularized tissue regeneration matrices formed by solid free form fabrication techniques |
| US6608182B1 (en) * | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| AU2399495A (en) | 1994-04-29 | 1995-11-29 | W.L. Gore & Associates, Inc. | Improved blood contact surfaces using endothelium on a subendothelial extracellular matrix |
| US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| ES2155534T3 (es) * | 1994-10-12 | 2001-05-16 | Focal Inc | Administracion dirigida por medio de polimeros biodegradables. |
| US6911216B1 (en) * | 1994-10-12 | 2005-06-28 | Genzyme Corporation | Targeted delivery via biodegradable polymers |
| US5914268A (en) * | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5716404A (en) * | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6281015B1 (en) * | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| US5855610A (en) * | 1995-05-19 | 1999-01-05 | Children's Medical Center Corporation | Engineering of strong, pliable tissues |
| US5766584A (en) * | 1995-06-02 | 1998-06-16 | Massachusetts Institute Of Technology | Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells |
| US6615071B1 (en) * | 1995-09-20 | 2003-09-02 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
| US5897987A (en) * | 1996-03-25 | 1999-04-27 | Advanced Reproduction Technologies, Inc. | Use of arabinogalactan in cell cryopreservation media |
| US6886568B2 (en) * | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
| AU766693B2 (en) * | 1998-11-24 | 2003-10-23 | Emory University | Transgenic circulating endothelial cells |
| US6328762B1 (en) * | 1999-04-27 | 2001-12-11 | Sulzer Biologics, Inc. | Prosthetic grafts |
| US6387116B1 (en) * | 1999-06-30 | 2002-05-14 | Pharmasonics, Inc. | Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts |
| US6461631B1 (en) * | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| AU2001243248A1 (en) * | 2000-02-23 | 2001-09-03 | Smith Kline Beecham Corporation | Method for the prevention or reduction of vascular access dysfunction |
| DE60130544T2 (de) * | 2000-03-13 | 2008-06-26 | Biocure, Inc. | Embolische zusammensetzungen |
| WO2001068158A1 (en) * | 2000-03-15 | 2001-09-20 | Orbus Medical Technologies Inc. | Coating that promotes endothelial cell adherence |
| KR20020086678A (ko) * | 2000-03-24 | 2002-11-18 | 가부시끼가이샤 메니콘 | 조직 등가물의 동결 보존 방법 및 동결 보존된 조직 등가물 |
| US6506398B1 (en) * | 2000-04-28 | 2003-01-14 | Hosheng Tu | Device for treating diabetes and methods thereof |
| US20020042131A1 (en) * | 2000-06-09 | 2002-04-11 | Organ Recovery Systems | Cryopreservation method using cryoprotective composition of propanediol and a vehicle solution |
| AU2001277112A1 (en) | 2000-07-21 | 2002-02-05 | Board Of Regents, The University Of Texas System | Device providing regulated growth factor delivery for the regeneration of peripheral nerves |
| WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| JP2002200161A (ja) * | 2000-10-24 | 2002-07-16 | Menicon Co Ltd | 培養皮膚代替物の製造方法およびそれにより得られる培養皮膚代替物 |
| US6565601B2 (en) * | 2000-11-15 | 2003-05-20 | Micro Therapeutics, Inc. | Methods for vascular reconstruction of diseased arteries |
| EP1389078A4 (en) * | 2000-12-27 | 2004-03-17 | Ortec International Inc | METHOD FOR THE PRODUCTION OF CRYCONSERVED COMPOSED LIVING CONSTRUCTS AND PRODUCTS PRODUCED FROM THEM |
| ES2621652T3 (es) * | 2001-01-16 | 2017-07-04 | Vascular Therapies, Inc. | Dispositivo implantable que contiene material de matriz reabsorbible y rapamicina para evitar o tratar enfermedades vasculoproliferativas |
| US6723131B2 (en) * | 2001-02-28 | 2004-04-20 | The Cleveland Clinic Foundation | Composite bone marrow graft material with method and kit |
| WO2003026489A2 (en) | 2001-09-28 | 2003-04-03 | University Of Florida | Biopolymer and biopolymer-cell compositions for nerve tissue repair |
| US7297540B2 (en) * | 2002-01-15 | 2007-11-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs |
| US20040047843A1 (en) * | 2002-02-12 | 2004-03-11 | Uab Research Foundation | Method for spinal cord reconnection |
| WO2003083044A2 (en) * | 2002-03-25 | 2003-10-09 | Condros, Inc. | Tissue analogs for in vitro testing and method of use therefor |
| US20050008629A1 (en) * | 2002-05-08 | 2005-01-13 | Interpore Orthopaedics, A Delaware Corporation | Encapsulated AGF cells |
| AU2003250858A1 (en) * | 2002-06-28 | 2004-01-19 | Novartis Ag | Use of organic compounds |
| FR2845691B1 (fr) * | 2002-10-10 | 2004-12-10 | Centre Nat Rech Scient | Nouvelles cellules endotheliales, anticorps diriges contre ces cellules et leur utilisation, notamment pour le criblage de substances inhibant l'angiogenese |
| US20040156878A1 (en) * | 2003-02-11 | 2004-08-12 | Alireza Rezania | Implantable medical device seeded with mammalian cells and methods of treatment |
| WO2004111207A1 (en) * | 2003-06-09 | 2004-12-23 | Centelion | Multicellular in vitro model of angiogenesis and methods for using the same |
| US8192348B2 (en) * | 2003-07-01 | 2012-06-05 | Regents Of The University Of Minnesota | Engineered blood vessels |
| GB0322789D0 (en) * | 2003-09-30 | 2003-10-29 | Lifeforce Group Plc | Blood pack for leukocyte banking |
| US20050106554A1 (en) * | 2003-11-19 | 2005-05-19 | Palecek Sean P. | Cryopreservation of pluripotent stem cells |
| US8067368B2 (en) * | 2004-01-27 | 2011-11-29 | The Ohio State University Research Foundation | Vascular endothelial growth factors and methods of their use |
| ATE506431T1 (de) * | 2004-04-23 | 2011-05-15 | Bioe Llc | Mehrfachlinien-vorläuferzellen |
| FR2869533B1 (fr) | 2004-05-03 | 2006-07-28 | Sedat Sa | Seringue pour interventions medicales et necessaire de reconstitution de substances extemporanees comportant une telle seringue |
| US7842304B2 (en) | 2004-10-29 | 2010-11-30 | Nexeon Medsystems, Inc. | Methods and apparatus for treating an injured nerve pathway |
| WO2006062871A2 (en) | 2004-12-08 | 2006-06-15 | Pervasis Therapeutics, Inc. | Materials and methods for minimally-invasive administration of a cell-containing flowable composition |
| DE602005022481D1 (de) | 2004-12-08 | 2010-09-02 | Pervasis Therapeutics Inc | Zusammensetzungen und deren verwendung für besseren gefässzugang |
| WO2006062909A2 (en) * | 2004-12-08 | 2006-06-15 | Pervasis Therapeutics, Inc. | Methods and compositions for enhancing vascular access |
| AU2006238892B2 (en) | 2005-04-21 | 2011-01-27 | Massachusetts Institute Of Technology | Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs |
| GB0509845D0 (en) | 2005-05-13 | 2005-06-22 | Btg Int Ltd | Preparation of therapeutic foam |
| US20090035346A1 (en) | 2005-06-21 | 2009-02-05 | Pervasis Therpeutics, Inc. | Methods and Compositions for Enhancing Vascular Access |
| JP5015160B2 (ja) | 2005-10-12 | 2012-08-29 | セルラー・バイオエンジニアリング・インコーポレイテッド | 再吸収可能な角膜ボタン（ｒｅｓｏｒｂａｂｌｅｃｏｒｎｅａｂｕｔｔｏｎ） |
| US7882863B2 (en) * | 2005-10-19 | 2011-02-08 | Cd Solutions, Llc | Apparatus and method for mixing and transferring medications |
| AU2006348410B2 (en) * | 2005-11-07 | 2011-12-15 | Industrie Borla S.P.A. | Vented safe handling vial adapter |
-
2006
- 2006-06-05 US US11/922,729 patent/US20090035346A1/en not_active Abandoned
- 2006-06-05 AU AU2006262682A patent/AU2006262682B2/en not_active Ceased
- 2006-06-05 EP EP20110001333 patent/EP2361591A3/en not_active Withdrawn
- 2006-06-05 SG SG201002482-6A patent/SG161258A1/en unknown
- 2006-06-05 CN CN2006800279776A patent/CN101257861B/zh not_active Expired - Fee Related
- 2006-06-05 WO PCT/US2006/021755 patent/WO2007001744A2/en not_active Ceased
- 2006-06-05 CA CA 2612751 patent/CA2612751A1/en not_active Abandoned
- 2006-06-05 CA CA 2818182 patent/CA2818182C/en not_active Expired - Fee Related
- 2006-06-05 ES ES06772165.4T patent/ES2541684T3/es active Active
- 2006-06-05 CN CN2010102362140A patent/CN101878757A/zh active Pending
- 2006-06-05 CN CN201210246619.1A patent/CN102743792B/zh not_active Expired - Fee Related
- 2006-06-05 SG SG2013075387A patent/SG195537A1/en unknown
- 2006-06-05 JP JP2008518189A patent/JP5632580B2/ja not_active Expired - Fee Related
- 2006-06-05 EP EP20060772165 patent/EP1901680B1/en not_active Not-in-force
-
2007
- 2007-12-19 IL IL188263A patent/IL188263A/en not_active IP Right Cessation
-
2012
- 2012-06-12 JP JP2012133043A patent/JP2012166084A/ja not_active Withdrawn
- 2012-07-05 IL IL220806A patent/IL220806A/en not_active IP Right Cessation
- 2012-11-02 US US13/667,227 patent/US9023377B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9023377B2 (en) | 2015-05-05 |
| CA2818182C (en) | 2015-04-14 |
| CN101878757A (zh) | 2010-11-10 |
| JP2008546406A (ja) | 2008-12-25 |
| IL188263A0 (en) | 2009-02-11 |
| ES2541684T3 (es) | 2015-07-23 |
| SG161258A1 (en) | 2010-05-27 |
| WO2007001744A2 (en) | 2007-01-04 |
| CN102743792B (zh) | 2014-09-24 |
| US20130210142A1 (en) | 2013-08-15 |
| US20090035346A1 (en) | 2009-02-05 |
| SG195537A1 (en) | 2013-12-30 |
| IL220806A0 (en) | 2012-08-30 |
| EP1901680B1 (en) | 2015-04-15 |
| CN101257861A (zh) | 2008-09-03 |
| EP2361591A3 (en) | 2011-12-21 |
| JP5632580B2 (ja) | 2014-11-26 |
| EP2361591A2 (en) | 2011-08-31 |
| WO2007001744B1 (en) | 2007-12-21 |
| CA2818182A1 (en) | 2007-01-04 |
| IL188263A (en) | 2014-05-28 |
| WO2007001744A3 (en) | 2007-10-04 |
| AU2006262682A1 (en) | 2007-01-04 |
| EP1901680A2 (en) | 2008-03-26 |
| AU2006262682B2 (en) | 2012-07-05 |
| CN102743792A (zh) | 2012-10-24 |
| JP2012166084A (ja) | 2012-09-06 |
| IL220806A (en) | 2014-05-28 |
| CN101257861B (zh) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9023377B2 (en) | Methods and compositions for enhancing vascular access | |
| CA2589597C (en) | Methods and compositions for enhancing vascular access | |
| US20100204783A1 (en) | Methods and compositions for enhancing vascular access | |
| ES2348961T3 (es) | Composiciones y su uso para aumentar el acceso vascular. | |
| WO2006062909A2 (en) | Methods and compositions for enhancing vascular access | |
| AU2012238220B2 (en) | Methods and compositions for enhancing vascular access | |
| AU2011211370B2 (en) | Methods and compositions for enhancing vascular access | |
| HK1143517A (en) | Compositions and their use for enhancing vascular access | |
| HK1112429B (en) | Compositions and their use for enhancing vascular access | |
| HK1174859A (en) | Methods and compositions for enhancing vascular access | |
| HK1178466A (en) | Methods and compositions for enhancing vascular access |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20170330 |